Use of bromocriptine in the treatment of normoprolactinemic infertility. 1987

K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito

The efficacy of bromocriptine therapy was studied in 84 normoprolactinemic infertile patients. Bromocriptine (2.5-5.0 mg/day) was given for at least 1 month. Bromocriptine therapy was effective in 54 of 84 cases (64%), including 6 of 15 (40%) cases with amenorrhea, 16 of 24 cases (67%) with anovulatory cycle, 9 of 15 cases (60%) with delayed ovulation and 23 of 30 cases (77%) with luteal phase defect. Sixteen cases were able to conceive with bromocriptine alone. Twenty-five patients who did not respond to bromocriptine were treated with a combination therapy consisting of bromocriptine and clomiphene. Of the 25 cases, 14 responded to the therapy, and 6 of them were able to conceive. The response of prolactin to domperidone (10 mg, i.v.) was significantly (p less than 0.01) higher in the group responding to bromocriptine than in the nonresponding group. These results indicate that the administration of bromocriptine is an effective therapy for patients with normoprolactinemic endocrine disorders, and that domperidone may be useful in selecting the candidates for bromocriptine therapy.

UI MeSH Term Description Entries
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004294 Domperidone A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. Apo-Domperidone,Domidon,Domperidon,Domperidon AL,Domperidon Hexal,Domperidon Stada,Domperidon-TEVA,Domperidona Gamir,Domperidone Maleate,Domperidone Maleate (1:1),Domperidone Monohydrochloride,Gastrocure,Motilium,Nauzelin,Novo-Domperidone,Nu-Domperidone,PMS-Domperidone,Péridys,R-33,812,R-33812,Ratio-Domperidone,Apo Domperidone,Domperidon TEVA,Gamir, Domperidona,Hexal, Domperidon,Maleate, Domperidone,Monohydrochloride, Domperidone,Novo Domperidone,Nu Domperidone,PMS Domperidone,R33,812,R33812,Ratio Domperidone,Stada, Domperidon
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
December 1986, Fertility and sterility,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
June 1982, Clinical reproduction and fertility,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
September 1979, Fertility and sterility,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
May 1986, The Journal of clinical endocrinology and metabolism,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
January 1980, Andrologia,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
November 1985, Fertility and sterility,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
January 1990, Journal of endocrinological investigation,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
September 1988, Ginecologia y obstetricia de Mexico,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
January 1990, Fertility and sterility,
K Ueda, and H Kato, and T Fujino, and K Nanjo, and H Noguchi, and F Numa, and A Narimatsu, and Y Nakamura, and T Torigoe, and T Ito
February 1983, Fertility and sterility,
Copied contents to your clipboard!